Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma
A phase 2 trial of camrelizumab, nab-paclitaxel, S-1 and anlotinib in gallbladder cancer and other biliary tract cancers, run by The First Affiliated Hospital of Zhengzhou University, now recruiting.
Overview
Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma is a phase 2, randomised interventional study registered as NCT06901622 by The First Affiliated Hospital of Zhengzhou University, with a registry enrolment figure of 50 participants, started 2024-11-08 and due to reach its primary completion in 2026-03-01. Interventions recorded: Camrelizumab, anlotinib, nab-paclitaxel, S-1, Camrelizumab, nab-paclitaxel, S-1. Conditions listed: Gallbladder Cancer and Extrahepatic Cholangiocarcinoma. Sites: China. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialAnlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment
Shares Tegafur, gimeracil and oteracil (S-1), Nab-paclitaxel, Anlotinib, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups) and the tag gallbladder-deep-dive.
- TrialDurvalumab Combined With S-1 as Adjuvant Therapy of Resectable BTC
Shares Tegafur, gimeracil and oteracil (S-1), Extrahepatic cholangiocarcinoma (perihilar and distal), Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
- TrialCamrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer
Shares Tegafur, gimeracil and oteracil (S-1), Camrelizumab, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
- TrialGem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT)
Shares Nab-paclitaxel, Extrahepatic cholangiocarcinoma (perihilar and distal), Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
- TrialAdebrelimab Plus S-1 for Resected Cholangiocarcinoma
Shares Tegafur, gimeracil and oteracil (S-1), Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer and the tag gallbladder-deep-dive.
- TrialEfficacy and Safety of Postoperative Concurrent Chemoradiotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma: A Multicenter Prospective Phase II Study
Shares Tegafur, gimeracil and oteracil (S-1), Extrahepatic cholangiocarcinoma (perihilar and distal), Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
- TrialSintilimab Combined With Ipilimumab (N01) Plus AG as First-line Therapy for uBTC.
Shares Nab-paclitaxel, Extrahepatic cholangiocarcinoma (perihilar and distal), Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
- TrialAn Open-label, Single-arm, Multicenter Exploratory Study of Adebrelimab Combined With Gemcitabine and Albumin-bound Paclitaxel as First-line Treatment for Biliary Tract Malignancies
Shares Nab-paclitaxel, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer and the tag gallbladder-deep-dive.